Introduction
Autism is a severe pervasive developmental disorder characterized by impaired language, communication and social skills, as well as by repetitive and stereotypic patterns of behavior. 1 Its incidence has dramatically risen from 2-5 to 15-60/10 000 children during the past two decades: broader diagnostic criteria and increased medical awareness have contributed to determine this trend, but the involvement of environmental factors is also likely. 2, 3 Despite strong familial components, clinical and genetic complexities have posed a major challenge to our understanding of autism pathogenesis. 3 Clinically, the behavioral expression of autism-predisposing genes can range from minimal autistic traits to full-blown autism, identifying a broad clinical entity referred to as 'autism-spectrum disorders' (ASDs). 3, 4 In addition, comorbidity with seizures and mental retardation occurs in up to 30% and in 80% of autistic patients, respectively. 5 Genetically, the picture is complicated by significant interindividual heterogeneity, numerous contributing loci, incomplete penetrance, phenocopies, gene-gene and gene-environment interactions. 3 Several lines of evidence strongly support a prenatal onset for developmental abnormalities later leading to autism: 6 post-mortem assessments of brains of autistic patients have unveiled early neurodevelopmental alterations including reduced programmed cell death and/or increased cell proliferation, altered cell migration, abnormal cell differentiation with reduced neuronal size and altered synaptogenesis; 3, 7 many children later diagnosed with ASD display motor abnormalities 8 and/or excessive body growth, 9 already on the day of birth or in early neonatal life. In addition, systemic signs and symptoms including macrosomy, 9 nonspecific enterocolitis, 10,11 immune dysreactivity 11 and renal oligopeptiduria, 12 pose autism as a multiorgan systemic disorder encompassing several developmental components, not restricted to the central nervous system (CNS).
Evidence linking altered energy metabolism to autistic disorder has been available for some time, including peripheral markers, such as increased plasma lactate levels, and rare instances of association between respiratory chain disorders and autism. 13, 14 Interest in assessing the role of mitochondria in this disorder has been revitalized by the association between autism and variants of the SLC25A12 gene, which encodes the predominant isoform of the mitochondrial aspartate (asp)/glutamate (glu) carrier (AGC) in brain. 15, 16 AGC belongs to a family of integral proteins that catalyze the transport of metabolites and cofactors across the inner mitochondrial membrane. 17 In particular, AGC is important in energy metabolism by transporting glutamate into mitochondria in exchange for matrix aspartate, a key regulatory step in the malate/aspartate reduced nicotinamide adenine dinucleotide (NADH) shuttle. 18, 19 Its two isoforms, AGC1 and AGC2, also named aralar(1) and citrin, are encoded by the SLC25A12 and SLC25A13 genes, located on human chromosomes 2q24 and 7q21.3, respectively.
19 AGC1 and AGC2 expression overlaps during early prenatal life, but diverges beginning in late gestation and into adulthood, with AGC1 predominantly expressed in the brain, heart and skeletal muscle, whereas AGC2 is mainly expressed in liver and kidney. 20, 21 In the CNS, AGC1 is highly expressed in neurons, whereas glial cells express both isoforms at much lower levels. 20, 21 Importantly, AGC activity is regulated by intracellular calcium (Ca 2 þ ) through four 'EF-hand' domains 22 located at its N-terminus, hanging into the intermembrane space. 18, 19 As Ca 2 þ concentrations in the mitochondrial intermembrane space and cytosol are in equilibrium, cytosolic Ca 2 þ can rapidly activate AGC transport, thereby increasing the NADH/NAD ratio in the mitochondrial matrix and consequently boosting electron flow through the respiratory chain and adenosine triphosphate (ATP) generation by oxidative phosphorylation. 18, 19, 23 Through this mechanism, AGC1 is important in the transduction of small Ca 2 þ signals to neuronal mitochondria. 19 An excessive amplitude and/or duration of Ca 2 þ spikes leading to AGC activation can, however, contribute to the formation of reactive oxygen species (ROS) and to oxidative stress. 24 Genetic and/or environmental factors could thus interfere with neuronal ATP production and with oxidative stress by affecting the AGC1 carrier, either directly or through Ca 2 þ homeostasis.
In this study, we have assessed AGC transport rates, SLC25A12 gene expression, Ca 2 þ concentrations and respiratory chain activity in the post-mortem temporocortical gray matter (Brodmann area 41/42 or 22) of six pairs of nonsyndromic ASD patients and sex-, ageand post-mortem interval (PMI)-matched controls (Table 1) . Neocortex from the superior temporal gyrus was selected, as it hosts structural and functional abnormalities well documented in autistic individuals. 25 Sequencing genomic DNA and cDNA from these same tissues, we have searched for polymorphisms and/or mutations in the SLC25A12 gene correlated with biochemical parameters. Finally, we have searched for SLC25A12 gene variants conferring autism vulnerability using a family-based association approach in 309 simplex and 17 multiplex families with a nonsyndromic autistic proband.
Materials and methods

Patient brain tissue information
Relevant clinical and demographic information was obtained from the Autism Tissue Program (www. atpportal.org) and is summarized in Table 1 . Patients were selected for the absence of CNS malformations or dysmorphology; controls were selected to match patients, based on sex, age (±2 years) and PMI. The same, or slightly larger paired patient-control samples, have been the object of recent reports. [26] [27] [28] Brain tissue processing Fresh frozen brain tissue samples dissected from the superior temporal gyrus (BA 41/42 or 22) of patients and controls were obtained through the Autism Tissue Program from the NICHD Brain and Tissue Bank and the Harvard Brain Tissue Resource Center. Cortical gray matter (100-200 mg) was suspended in a buffer containing 250 mM sucrose and 10 mM TRIS, pH 7.4 and homogenated using a Teflon glass potter. Cell debris was pelleted by centrifugation at 800 Â g and discarded. Cytochrome c oxidase (COX) and For B5569, the last report summarizing the pharmacological therapy dates to less than a year prior to death.
Altered calcium homeostasis in autism L Palmieri et al citrate synthase (CS) activities were measured, according to the standard procedures. 29 Mitochondria from brain homogenates were harvested by centrifugation at 13 000 Â g for 12 min at 4 1C. Mitochondriaenriched pellets and postmitochondrial supernatants were then stored at À80 1C until further processing. Total RNA was extracted using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to standard methods, and RNA quality was checked using a Bioanalyzer (Agilent, Santa Clara, CA, USA); all RNA samples used in this study displayed RNA integrity number (RIN) values > 6.9. DNA was recovered by phenol/chloroform extraction and ethanol precipitation, following tissue digestion in proteinase K overnight at 55 1C.
Solubilization and functional reconstitution of AGC1 Proteins from tissue homogenates or isolated mitochondria were solubilized in 0.4% Triton X-114 (w/v), 20 mM Na 2 SO 4 , 10 mM MOPS, pH 7.0, at a final concentration of 1.9-3.5 mg protein per ml (0.5-1.5 mU CS ml À1 ); 5 mM ethylene glycol tetraacetic acid (EGTA) was added 10 min prior to solubilization, where specified. After incubation for 20 min at 4 1C, the mixture was spun at 138 000 Â g for 12 min. Triton-solubilized proteins were immediately incorporated into phospholipid vesicles by cyclic removal of the detergent using a hydrophobic column. 30 The composition of the initial mixture use for reconstitution was: 25 ml of Triton-solubilized extract, 70 ml of 10% Triton X-114, 110 ml of 10% phospholipids in the form of sonicated liposomes, 20 mM glutamate, 10 mM MOPS (pH 7.0), 0.4 mg cardiolipin and water to a final volume of 700 ml. Deionized Milli-Q water was used for preparation of all solutions. Transport at 25 1C was started by adding 40 mM [
14 C]-aspartate to the proteoliposomes and terminated at each time interval by adding 30 mM pyridoxal 5 0 -phosphate and 10 mM bathophenanthroline. 30 Entrapped radioactivity was counted. The initial rate of transport was calculated from the time course of isotope equilibration. 30 Expression analysis by real-time PCR Total RNA was reverse-transcribed with the GeneAmp RNA PCR Core kit (Applied Biosystems, Foster City, CA, USA). Probes and primers for AGC1, AGC2 and PiC were purchased from Applied Biosystems. The amount of each cDNA was measured using the comparative method (2 ÀDDC t ; User Bulletin 2 P/N 4303859, Applied Biosystems), and the human b-actin was used as standard normalizer.
Western blotting
Western blotting of brain homogenates was performed using polyclonal antibodies raised in rabbit against recombinant AGC1 23 or mouse monoclonal antibodies against the b subunit of human F 1 -ATPase (cod. 612519; BD Biosciences, San José, CA, USA). Antigen-antibody complexes were detected using anti-rabbit or anti-mouse IgG-coupled horseradish peroxidase (cod. 31460 or 31430; Pierce, Rockford, IL, USA), in combination with the Amersham ECL system (GE Healthcare, Piscataway, NJ, USA).
Fluorimetric measurement of Ca 2 þ concentrations Free Ca 2 þ levels were measured in postmitochondrial supernatants by the fluorescent indicator Fura-2. Following incubation of each postmitochondrial supernatant (20 mg protein) with 1 mM Fura-2 pentapotassium salt (F6799; Molecular Probes, Eugene, OR, USA), the ratio of fluorescence intensities detected at 510 nm at two different excitation wavelengths (340 and 380 nm) was determined using a PerkinElmer LS 50 spectrofluorimeter. The indicator calibration and Ca 2 þ measurements were performed at room temperature, as described. 31 Quantification of mitochondrial protein oxidation Carbonylated mitochondrial proteins were detected using the OxyBlot Protein Oxidation Detection Kit (Chemicon, Temecula, CA, USA). 2,4 dinitrophenylhydrazine-derivatized crude protein extracts were dot blotted, incubated with a primary antibody against DNP-hydrazone followed by a horseradish peroxidase-conjugated secondary antibody, visualized using the ECL chemiluminescent detection method and quantified by densitometry.
SLC25A12 cDNA and genomic DNA sequencing The SLC25A12 coding sequence was screened between bp þ 13 and þ 2941, relative to the ATG translation start site, using cDNA and genomic DNA obtained from the same six ASD-control pairs assessed for transport and gene expression studies. Primer sequences and PCR conditions are summarized in Supplementary Table S1 . DNA sequencing was performed using a CEQ8000 DNA sequencer (Beckman-Coulter, Fullerton, CA, USA). All singlenucleotide polymorphisms (SNPs) identified by DNA sequencing were confirmed by restriction digest.
Subjects recruited for the family-based association study Our clinical sample includes 309 simplex and 17 multiplex families with a nonsyndromic autistic proband (Supplementary Table S2 ), encompassing a total of 346 patients and 120 unaffected siblings. Demographic and clinical characteristics of ASD patients are summarized in Supplementary Table  S3 . Inclusion criteria and diagnostic screening methods used to exclude probands with syndromic autism have been previously reported. 32 Briefly, patients fulfilling DSM-IV diagnostic criteria for autistic disorder 1 were screened for nonsyndromic autism using MRI, electroencephalogram (EEG), audiometry, urinary amino acid and organic acid measurements, cytogenetic and fragile-X testing. Patients with dysmorphic features were excluded even in the absence of detectable cytogenetic alterations. Patients with sporadic seizures (that is, < 1 every 6 months) were included; patients with frequent seizures or focal neurological deficits were excluded. Large subsets of Altered calcium homeostasis in autism L Palmieri et al patients were assessed for adaptive functioning using the Vineland Adaptive Behavior Scales, for autistic behaviors using the official Italian version of the Autism Diagnostic Observation Schedule and the Autism Diagnostic Interview-Revised, 33, 34 as soon as these were made publicly available in 2006, for intelligence quotient (IQ) using either the Griffith Mental Developmental Scales, the Coloured Raven Matrices, the Bayley Developmental Scales or the Leiter International Performance Scale. Given the use of different scales in different clinical centers and the generally low reliability of IQ measurements in autistic patients, IQ scores were dichotomized as < 70 or X70 (that is, presence/absence of mental retardation) and are presented in Supplementary  Table S3 according to this criterion. In addition, our sample encompasses a total of 120 unaffected siblings, from 92 families with one unaffected sibling, 9 families with 2, 2 families with 3 and another with 4 unaffected siblings, whereas 222 families with an autistic proband include no unaffected brothers and sisters. The definition of 'unaffected sibling' is based upon the clinical judgement of the same clinicians responsible for the DSM-IV diagnosis of autistic disorder in the affected sibling. All parents gave written informed consent for themselves and for their children, using the consent form approved by the Institutional Review Board of University 'Campus Bio-Medico' (Rome, Italy).
Genotyping
A total of 11 SNPs spanning the SLC25A12 locus were genotyped either by TaqMan or by SNPlex (Supplementary Table S4 ). Probes for TaqMan and SNPlex were synthesized by the manufacturer and used according to manufacturer's guidelines (Applied Biosystems).
Biochemical and morphological endophenotypes
Head circumference, serotonin (5-HT) blood levels, and urinary peptide excretion rates were measured, as previously described.
32,35
Statistical analyses Case-control contrasts were performed using the Wilcoxon's signed-ranks test for enzymatic and asp/ glu transport activity data, and the paired Student's t-test for Ca 2 þ levels, depending upon normality and variance homogeneity which were tested with the Levene and Kolmogorov-Smirnov tests, respectively, as implemented by the SPSS software package (ver. 14.0). Hardy-Weinberg equilibrium was tested using the w 2 statistic, as implemented by the Haploview software (available at http://www.broad.mit.edu/ mpg/haploview/index.php) 36 which extracts a maximal set of unrelated individuals from the total sample, and by the HWE software (available at http://linkage.rockefeller.edu/soft/linkutil/), used to analyze separately mothers, fathers, autistic patients, and unaffected siblings (including only one autistic and unaffected sibling per family). Family-based single-marker and haplotype association tests were performed using the family-based association test (FBAT) statistic (S = ST Â X, where T is the phenotypic trait and X is the marker value), as implemented by the FBAT software package (available at http:// www.biostat.harvard.edu/~fbat/fbat.htm), under an additive model. 37 The FBAT statistic stems from the transmission/disequilibrium test (TDT), where preferential allelic transmission from heterozygous parents to affected offspring is tested by applying the (bÀc) 2 /(b þ c) statistics and the w 2 ('McNemar test').
38
Maternal and paternal transmissions were also analyzed separately using the same FBAT approach. To further ensure reliability, despite lower statistical power, we also performed single-marker TDTs on complete trios only and randomly choosing one trio per multiplex family, by using TDTPHASE (http:// www.rfcgr.mrc.ac.uk/~fdudbrid/software/unphased/), 39 which implements likelihood ratio tests based on loglinear models. Quantitative traits were analyzed by (1) quantitative transmission/disequilibrium test (qTDT), as implemented by the same FBAT statistic, where T is the quantitative trait of interest (instead of a dichotomic affected/unaffected status as in the TDT), 37 and by (2) parametric analysis of variance (ANOVA) based on genotype distributions, or nonparametric Kruskal-Wallis ANOVA, implemented whenever the assumptions of normality and/or variance homogeneity could not be satisfied despite data transformation. Patients treated with selective 5-HT-reuptake inhibitors were excluded from analyses of 5-HT blood levels. Linkage disequilibrium (LD) was tested using Haploview, 36 which calculates D 0 coefficients reported here and constructs haplotype blocks by implementing the approach of Gabriel et al. 40 The consistency of these D 0 coefficients was also verified using the HBAT command in FBAT on pedigree data. Analyses were carried out merging together 290 Italian and 36 CaucasianAmerican families (Supplementary Table S2 ), after population structure analyses (see Supplementary Methods in ref. 27 for a detailed description) provided no evidence of major genetic dyshomogeneity in a subgroup of 155 Italians and 24 CaucasianAmericans autistic patients randomly chosen one per family, genotyped at 90 unlinked SNPs distributed genome wide and analyzed using the Structure software. 41 Data are expressed as mean ± s.e.m., except for head circumference and urinary peptide excretion rates, expressed as median percentile ± interquartilic range. Nominal two-tail P-values are reported. Statistical significance is set by applying a Bonferroni correction for multiple testing as follows: (1) Hardy-Weinberg analyses: P < 0.05/55 (11 SNPs Â 5 sets of analyses by status) = 0.00091; (2) haplotype analyses: P < 0.05/2 (two haplotype blocks) = 0.025; single-marker analyses: P < 0.05/5 (two haplotype blocks þ three SNPs outside the blocks) = 0.01. We did not apply a Bonferroni correction considering all 11 SNPs as independent observations, because the existence of two haplotype blocks implies by definition the nonindependence of single-marker and endophenotypic analyses involving SNPs contained within each block. No correction for multiple testing was adopted for the two ethnic groups, given the outcome of population structure analyses described above.
Results
AGC activity is boosted by excessive Ca 2 þ levels in autistic brains AGC activity, normalized by CS activity to adjust for differences in absolute mitochondria tissue content, displays a prominent threefold increase in neocortical homogenates from nonsyndromic autistic patients compared to matched controls in all six pairs (Wilcoxon's test: Z = À2.201, P < 0.05; Figure 1a , left). AGC1 protein levels only show a very modest, nonsignificant increase (Supplementary Figure S1) . Instead, Ca 2 þ chelation by EGTA reduces asp/glu exchange rates to a much larger extent in patients than in controls (2.1-vs 0.35-fold, respectively), reducing case-control differences to only 36.1% (Figure 1a , middle). No difference between patients and controls is anymore detectable upon reconstitution of protein extracts from isolated mitochondria (P = 0.17; Figure 1a , right). These results strongly point toward excessive Ca 2 þ concentrations as most likely responsible for increased asp/glu exchange rates in the brains of autistic patients.
To further test this hypothesis, two aliquots of isolated mitochondria from each control have been exposed in parallel experiments either to his/her own postmitochondrial supernatant, or to the postmitochondrial supernatant of his/her matched autistic patient (Figure 1b, left) . Remarkably, the patient supernatant activates asp/glu exchange rates to a significantly larger extent than the control supernatant in all six pairs, yielding mean 3.2-vs 1.7-fold increases, respectively (P < 0.05). This difference between case and control supernatants is no longer significant following Ca 2 þ chelation by EGTA ( þ 119.8 vs þ 82.3%, respectively; P = 0.074; Figure 1b , right). These results confirm the primary role of excessive Ca 2 þ levels in boosting AGC activity in the brains of autistic patients. Experiments employing mitochondria from autistic patients provide superimposable results (Figure 1c ), except for a statistically significant elevation of asp/glu transport rates over control levels retained also following exposure of the supernatants to EGTA (Figures 1b vs 1c, right panels) .
Finally, direct measurements of Ca 2 þ concentrations in the postmitochondrial supernatant revealed consistently and significantly increased Ca 2 þ levels in all six ASD patients compared to matched controls (paired Student's t-test: t = À5.259, 5 degrees Figure 1 Aspartate/glutamate exchange rates are activated by enhanced calcium levels in neocortical tissue of autistic patients. (a) Aspartate/glutamate carrier (AGC) activity in neocortical tissue homogenate, in the absence (left) or in the presence (middle) of 5 mM ethylene glycol tetraacetic acid (EGTA), and in mitochondria isolated from the same tissue specimens (right); (b) AGC activity in mitochondria isolated from the neocortical tissue of each of six controls exposed to the postmitochondrial supernatant from his/her matched autistic patient (autism-spectrum disorder, 'ASD' label) or to his/her own supernatant ('controls' label), preincubated in the absence (left) or in the presence (right) of 5 mM EGTA; (c) AGC activity in mitochondria isolated from the neocortical tissue of each of six ASD patients, exposed to the his/her own postmitochondrial supernatant ('ASD' label) or to the supernatant of his/her matched control ('controls' label), preincubated in the absence (left) or in the presence (right) of 5 mM EGTA.
of freedom (d.f.), P < 0.01; Figure 2a ). This increase is entirely independent of a positive or negative history of seizures, antiepileptic medications or seizure-related death (patients N = 3 positive vs 3 negative history, Ca 2 þ levels: t = 0.288, 4 d.f., P = 0.788; autistic/control Ca 2 þ ratios: t = À0.699, 4 d.f., P = 0.523; Figure 2b ).
AGC activation increases mitochondrial metabolism and oxidative stress By increasing the availability of reducing equivalents in the mitochondrial matrix through AGC, enhanced cytosolic Ca 2 þ can be predicted to steadily boost mitochondrial metabolism and oxidative phosphorylation. 18, 19, 23 Indeed, transcript amounts of the mitochondrial phosphate carrier (PiC), AGC1, and AGC2 (expressed at much lower levels compared to AGC1), are all increased (Supplementary Figure S2) . Also COX activity is elevated to a similar extent in all six autistic patients compared to their matched controls (P < 0.05; Figure 3a) . Ca 2 þ -triggered increases of the NADH/NAD ratio in the mitochondrial matrix and of the electron flow through the respiratory chain could potentially foster oxidative stress in genetically liable individuals. 24 Markers of oxidative damage show an impressive threefold increase in autistic brains compared to controls, with mean carbonylated mitochondrial protein content up by 202.3% (Figure 3b ). However, this increase does not reach statistical significance in our sample (P = 0.12) due to four patients displaying large increases in markers of oxidative damage ( þ 147, þ 204, þ 393 and þ 492%), whereas patients in pairs 2 and 6 show levels comparable to those recorded in their matched controls (À7 and À15.5%, respectively; Figure 3b ). The latter results likely reflect elevated oxidative stress in one control (UMB1185 in pair 2), and normal levels in one autistic subject (B5144 in pair 6).
No evidence of SLC25A12 gene contributions to autism vulnerability Sequencing of the AGC1-encoding SLC25A12 cDNA and genomic DNA in these same six case-control pairs does not detect any nonsynonymous coding mutation. Only five known SNPs are identified, two located in intron 1 (rs3821092 and rs12991441), one synonymous SNP present in the coding sequence (rs1878583, C99T) and two SNPs found in the 3 0 -untranslated region (rs3035825 and rs11757); none of them is consistently associated with the biochemical trends described above (Supplementary Table S5) .
A family-based association study was then performed on 307 simplex and 17 multiplex families to assess whether gene variants at the SLC25A12 locus could possibly contribute to autism pathogenesis in a subgroup of patients not sufficiently represented in our post-mortem sample. The 11 SNPs employed in this study are distributed throughout the SLC25A12 locus (Figure 4 , top) and are in Hardy-Weinberg equilibrium (Supplementary Table S6 ). The LD pattern present at this locus in our sample and depicted in Figure 4 is very similar to the LD pattern found by the International HapMap Project in their Caucasian CEPH population (that is, Utah residents with ancestry from northern and western Europe; see www.hapmap.org). Despite tight LD both within and between the two haplotype blocks present in the SLC25A12 locus (Figure 4) , no evidence of singlemarker (Table 2a and Supplementary Table S7) or haplotypic (Table 2b ) association with autism is found in our sample. No parent-of-origin effect is detected (data not shown). We also find no association with morphological and biochemical endophenotypes, including macrocephaly and elevated serotonin (5-HT) blood levels (Supplementary Tables  S8 and S9) , whereas contributions to enhanced peptiduria, compatible with physiological AGC roles in the urea cycle, 19 may be provided by haplotype 1-2-2 at SNPs rs2292813, rs7586207, rs1878583 and rs6724337 (Supplementary Tables S8 and S9) . Similarly, negative results are obtained restricting analyses to families with probands aged < 16 years for cranial circumference and to families with probands aged < 11 years for serotonin blood levels (data not shown).
A SLC25A12 gene variant may confer protection in unaffected siblings Single-marker analyses point toward the possible existence of a protective SLC25A12 gene variant preferentially transmitted from heterozygous parents to unaffected siblings of autistic patients. Using either FBAT (Table 2a) or TDT (Supplementary Table S7) , we obtain nominal P < 0.05 for several SNPs and a significant P < 0.01 at rs17581284. SNP rs17499593 displays a statistically significant difference between patients and unaffected siblings (FBAT Z = À3.86, P < 0.0001; TDT w 2 = 18.6, 1 d.f., P < 0.0001). Instead, haplotype analyses yield global P-values that do not reach our threshold of significance for either of the two blocks (Table 2b) , likely due to the relatively small sample of families with unaffected siblings available for this study. One gene variant, marked by haplotype 1-1-2 in block 1 and by haplotype 2-2-1-2-2 in block 2, reaches a nominal P-value of about 0.01. The allele frequency of this haplotype is estimated at approximately 23-26% (Table 2b) , making it a relatively common variant among unaffected siblings.
Discussion
This study reports increased asp/glu exchange rates and significantly higher Ca 2 þ concentrations in postmortem neocortical tissue specimens of six nonsyndromic autistic patients compared to age-, sex-and PMI-matched controls. Altogether, our results strongly support excessive Ca 2 þ levels as primarily responsible for the observed activation of asp/glu exchange rates, whereas genetic contributions appear neither widespread nor necessary, at least in our postmortem and genetic samples.
Indeed the AGC activation documented here is (1) EGTA sensitive (Figures 1a-c) , (2) recorded only in the presence of the postmitochondrial supernatant, and absent in reconstituted protein extracts from isolated mitochondria (Figure 1a) , and (3) significantly more prominent when AGC reconstituted from mitochondrial membranes of each control is exposed to the postmitochondrial supernatant of his/her matched ASD case, than to his/her own supernatant (Figure 1b) . Measurements employing AGC reconstituted from mitochondrial membranes of each ASD patient exposed either to their own supernatant or to the supernatant of his/her matched control, essentially confirm the latter result (Figure 1c ). The only difference between these two complementary approaches is that AGC reconstituted from mitochondrial membranes of ASD patients retains a statistically significant elevation of asp/glu transport rates over control levels also following exposure to EGTA (Figure 1c ). This result nicely parallels the residual difference observed with homogenates (but not with isolated mitochondria), indicating that the higher Ca 2 þ levels present in the patient supernatant likely render equal concentrations of EGTA less effective, as compared to control supernatant. Most importantly, direct measurements of neocortical Ca 2 þ concentrations clearly demonstrate a significant elevation of neocortical Ca 2 þ levels in all autistic patients compared to controls (Figure 2a) . Finally, the thorough cDNA sequencing performed in our post-mortem cases, the highly favorable LD pattern present at the SLC25A12 locus (Figure 4) , the number of informative SNPs assayed in our family-based association study, the similar extent of asp/glu transport found in the protein extracts from isolated mitochondria of patients and controls (Figure 1a , right panel), the nonspecific generalized transcriptional activation of mitochondrial transporters (Supplementary Figure S1) , which does not translate into noticeable increases in AGC1 protein amounts (Supplementary Figure S2) , all strongly argue against genetic mutations or functional polymorphisms at the SLC25A12 locus as primarily responsible Figure 4 High linkage disequilibrium (LD) at the SLC25A12 locus. Genomic structure, genotyping markers, D 0 values Â 100 (that is, LD measure ranging 0-100) in our patients and first-degree relatives, and LD blocks at the SLC25A12 locus, according to the Haploview software. 36 Altered calcium homeostasis in autism L Palmieri et al 
À1.688
Altered calcium homeostasis in autism L Palmieri et al for the increase in AGC activity observed in our sample. Increased AGC transport rates, COX activities and Ca 2 þ levels consistently recorded in all six neocortical specimens from ASD patients crossvalidate each other, confirming the reliability and biological significance of these findings. This consistency argues against spurious effects exclusively due to seizures or drug treatment at the time of death. Potential confounding factors are inevitably intermingled with autism in our post-mortem sample, as they are at the phenotypic level in real life. Approximately 80% of autistic patients indeed have mental retardation and up to 30% a positive history of seizures, for which they often times receive pharmacological treatment. 5 Our post-mortem sample, though small, faithfully reflects the ASD population in terms of comorbidity. Indeed, three out of six ASD patients having a positive history for seizures, were receiving antiepileptic drugs at the time of death, and some of them may have undergone a seizure-related death, as summarized in Table 1 . Furthermore, several antiepileptic drugs taken at the time of death either directly or indirectly modulate Ca 2 þ levels. In principle, we cannot exclude that epilepsy could partly contribute to generate oxidative stress in the neocortex of autistic patients. However, our three seizure-positive and three seizure-negative ASD patients display absolutely no difference in supernatant Ca 2 þ concentrations and in matched patient/control Ca 2 þ ratios (Figure 2b ), nor do they differ in any AGCrelated measure (Figure 1) . For example, patients B5342 and B5144 display the largest elevation in Ca 2 þ levels: the former is seizure-positive, the latter seizure-negative (Figure 2a) . Patients B5569 and UMB4721 display some of the largest increases in asp/glu exchange rates (see pairs 2 and 3 in Figures 1a  and b) despite normal EEG reports, no history of seizure, and causes of death unrelated to seizures (Table 1) . Similarly, at least two patients, namely (a) Single-marker family-based association test (FBAT), performed using the FBAT software under an additive model; 37 (b) haplotype-based intrafamilial association test for autistic patients and unaffected siblings, performed using the HBAT command in the FBAT software, under an additive model. 37 The two haplotype blocks depicted in Figure 4 are analyzed separately. Only haplotypes with estimated frequencies > 1% are listed. FBAT output variables: N, number of informative nuclear families; S, test statistic (that is, genotypic distribution in the offspring conditioned on affection status and parental genotypes); E(S), expected value for S; Var(S), variance of S under the null hypothesis of no linkage and no association. P-values < 0.05 and < 0.01 are highlighted in bold and gray, respectively. UMB4721 and B5144 (see pairs 3 and 6 in Figures 1a  and b) , were not taking psychoactive drugs at the time of death; pharmacological treatments were also quite different from patient to patient (Table 1 ). Also differences in PMI cannot explain our results. Mean PMI values are neither significantly different between patients and controls (see note c in Table 1 ), nor are they correlated with AGC activation, as pair 1 displays the strongest AGC activation induced by the supernatant of the autistic patient (Figure 1b) , whereas her PMI is shorter than the PMI of her matched control (Table 1 ). In summary, altered Ca 2 þ homeostasis is the only factor shared by all autistic cortical tissue samples (Figure 2a) , able to boost AGC activity, 18, 19, 23 and previously linked to the pathogenesis of autism per se. 42 The existence of altered Ca 2 þ signaling in autism has been suggested in recent years by several lines of research. 42 Gain-of-function mutations in the L-type voltage-gated Ca 2 þ channel Ca v 1.2 (CACNA1C) cause Timothy syndrome, a multisystem disorder including mental retardation and autism. 43 Similarly, mutations in the L-type voltage-gated Ca 2 þ channel Ca v 1.4 (CACNA1F) cause the incomplete form of X-linked congenital stationary night blindness (CSNB2): gain-of-function mutations cause CSNB2 frequently accompanied by cognitive impairment and either autism or epilepsy, whereas CSNB2 due to lossof-function mutations is not accompanied by these symptoms. 44 All of these gain-of-function mutations prevent voltage-dependent channel inactivation leading to excessive Ca 2 þ influx. Also mutations indirectly yielding increased cytosolic Ca 2 þ levels or amplifying intracellular Ca 2 þ signaling by hampering Ca 2 þ -activated negative feedback mechanisms have been found associated with autism. 42, 45 The bioelectrical instability resulting from these mutations nicely parallels the high prevalence of seizures and/or EEG abnormalities present among autistic individuals.
Elucidating the process underlying the abnormal Ca 2 þ homeostasis described in this study is of utmost importance. Unfortunately post-mortem studies do not allow us to determine whether the enhanced Ca 2 þ levels documented in Figure 2a primarily reflect excessive in vivo extracellular Ca 2 þ concentrations, intracellular Ca 2 þ storage, or both; these possibilities will have to be teased out using cell culture paradigms. However, due to the dynamic nature of Ca 2 þ homeostasis, in either case cytosolic Ca 2 þ spikes can be predicted to display increased amplitude and/or duration, 46 resulting in enhanced AGC transport activity. Although rare de novo mutations raising intracellular Ca 2 þ levels can occasionally cause autism, a more likely scenario envisions either the coexistence in the same individual of several unfavorable common gene variants, or environmental and stochastic contributions acting upon a vulnerable genetic background. According to post-mortem and in vivo studies, an ongoing immune response could provide such a contribution by raising intracellular Ca 2 þ levels through cytokines, such as tumor necrosis factor-a and receptors, like CD38. 28, 47, 48 Indeed, the existence of an immune dysreactivity is also supported by the association between macrocephaly and macrosomy in autism with a history of immune/ allergic disorders, either in the patient or in his/her first-degree relatives. 9 Immune mechanisms may also mediate the vulnerability to autism conferred by recently described 16p11.2 microdeletions. 49 Another predicable pathophysiological consequence of an excessive, immune-driven Ca 2 þ entry into cells would be a progressive decrease in bone density, which has been described in at least two reports 50, 51 and may be frequently overlooked especially in younger patients. Finally, an 8-year-old female control (case no. UMB1706) was excluded from this study after consistently showing an EGTA-sensitive, 50-75% increase in asp/glu exchange rates. Interestingly, this girl died of a heart transplant rejection, and it is very intriguing that a massive immune response was followed in a nonautistic individual by an AGC activation reaching levels intermediate between those recorded in autistic patients and in other controls. Clearly, an immune response can raise Ca 2 þ levels and boost asp/glu exchange rates, as reported in the present study. However, the opposite could also occur: mutations or polymorphic variants in genes encoding Ca 2 þ channels or glutamate receptors could produce an increase in intracellular Ca 2 þ and/or in oxidative stress (see below), able to trigger an immune response similar to the one observed in autistic brains. We are currently in the process of correlating AGC activity and levels of oxidative stress with markers of immune activation, measured in the same tissue specimens assessed in this study.
We found no evidence of genetic contributions to autism vulnerability by SLC25A12 gene variants in our sample. These negative findings are in accordance with several prior reports. 14, 52, 53 In addition to obvious genetic heterogeneity in complex disorders, other factors could have potentially contributed to the repeated nonreplication of the two initial positive reports: 15, 16 (1) prominent differences in LD patterns, previously well documented for example at the PRKCB1 locus 27 between our sample and an Irish sample largely overlapping with the one assessed by Segurado et al.;
16 (2) spurious positive findings based on the two SNPs (rs2292813 and rs2056202) displaying the lowest heterozygosity (HZ) in the region (see observed HZ in Supplementary Table S6); (3) possible genetic contributions to a clinical endophenotype specifically characterized by prominent routines and rituals. 54 In our sample, the presence of motor stereotypies at intake is not significantly associated with allele G at rs7586207 in haplotype block 1 (w 2 = 1.527, 2 d.f., P = 0.466), or allele T at rs6724337 in haplotype block 2 (w 2 = 2.488, 2 d.f., P = 0.288). Altogether, we do not exclude that rare polymorphisms or functional variants located outside the genomic regions sequenced here could conceivably provide contributions to enhanced SLC25A12 gene expression, although this seems rather unlikely given the tight LD pattern present in the region (Figure 4) . Instead the present study clearly demonstrates that these genetic variants, if at all present, play a minor role compared to the extent of AGC activation produced by excessive Ca 2 þ levels in the neocortex of ASD patients.
Our results point toward the possible existence of a protective SLC25A12 gene variant in a sizable group of unaffected siblings. This cannot be conclusively demonstrated with our sample size of 104 families including one or more unaffected sibling. Unfortunately, no other study has to this date reported on unaffected siblings [14] [15] [16] [52] [53] [54] and genotyping for the Autism Genetic Resource Exchange (AGRE) data set is only available for the same two SNPs discussed above (rs2292813 and rs2056202), displaying low informatives and in the case of rs2292813 also located outside of the haplotype blocks depicted in Figure 4 . It will be important to see whether our results are confirmed in larger samples, for at least two reasons: on one hand, they suggest that the status of 'unaffected sibling' could define an individual possessing genetically determined compensatory mechanisms not available to autistic patients, rather than merely identifying family members who have not inherited the full array of disease-producing alleles. Our recent identification of another protective variant in the glyoxalase I gene, 35 in conjunction with gain-of-function mutations in the CACNA1F gene consistently yielding night blindness while causing autism or epilepsy only in a subset of carriers, 44 provide converging evidence of genetic backgrounds effectively protecting from autism. On the other hand, our results would provide further support for key contributions of Ca 2 þ -triggered AGC1 activity to autism pathogenesis. Increased asp/glu exchange rates provide more reducing equivalents (that is, NADH) to the respiratory chain and could foster oxidative stress, 24 which was previously found increased measuring peripheral markers in autism. 55 Also overexpression of AGC1 in cell culture has been recently found associated with a biphasic response, characterized initially by enhanced neurite outgrowth, which subsequently slows down and ends in early cell death. 56 This response is seemingly compatible with an initial overproduction of ATP paralleled by a progressive build up of oxidative stress leading to cell damage. Oxidative stress, in addition to lipid and protein oxidation, 55 can also produce genomic instability and stimulate cell cycle progression, pathophysiological events likely to be important in autism pathogenesis 9, 57, 58 In this regard, the interindividual variability in oxidative damage reported in our study is not at all surprising, as the balance between ROS production and antioxidant agents leaves ample room for genetic and environmental influences.
The present results can potentially pave the path to targeted preventive and therapeutic strategies. One important example is represented by thimerosal, an ethyl-mercury compound used as a preservative in vaccines. 59, 60 Thimerosal has drawn attention following initial anecdotal reports by some parents linking vaccinations to behavioral regression and to the onset of autism in their child within a matter of days or few weeks. Thimerosal is a Ca 2 þ -mobilizing agent, capable of releasing Ca 2 þ from intracellular stores and increasing Ca 2 þ entry. 61 Despite its short half-life compared to inorganic mercury, it undergoes preferential accumulation in the CNS, affecting the microglia and producing strain-dependent neurotoxic effects in rodents. 62, 63 This strain dependency, in conjunction with the present data, suggests that thimerosal could contribute to produce an unbalanced Ca 2 þ homeostasis in genetically vulnerable individuals. Indeed, a postnatal exposure to thimerosal is not reconcilable with the prenatal onset of neurodevelopmental anomalies leading to autism. Also large retrospective epidemiological studies confirm that thimerosal neither causes autism, nor provides large-scale contributions to its pathogenesis. 2, 60 However, our results suggest that thimerosal could conceivably precipitate an abrupt onset in a subset of children who would have otherwise developed autistic symptoms more insidiously. At the same time, we cannot exclude that thimerosal and other Ca 2 þ -mobilizing environmental factors could also push genetically vulnerable individuals along the autism-spectrum toward more severe forms of the disease. On the basis of the present study, the elimination of thimerosal from vaccines, undertaken in the United States and Canada, is a well-justified safety measure.
Pharmacological treatments able to modulate extracellular Ca 2 þ entry, intracellular Ca 2 þ release from the endoplasmic reticulum or putative upstream immune mechanisms affecting either or both the pathways are, at least in principle, already available. However, caution should be exercised in translating the present findings into therapeutic interventions prior to at least one replication in an independent cohort of brain samples and to assessments of Ca 2 þ homeostasis in vivo. In particular, our findings in no way support the use of Ca 2 þ chelation as a therapeutic approach in autism. Ca 2 þ chelation has not only been purported of benefit in few anecdotal reports and small-sized open trials, but also carries a substantial risk to produce hypocalcemia, resulting in recent deaths of autistic children. 64, 65 Pharmacologically reducing Ca 2 þ entry into cells or blunting the oxidative damage produced by AGC activation seemingly represent more amenable and less dangerous therapeutic strategies. It is nonetheless difficult to predict the actual efficacy of treatments initiated during childhood on pathogenetic mechanisms active since early prenatal development. In this regard, the identification and functional characterization of protective SLC25A12 gene variants, if existent, could provide additional critical information on the contribution of AGC activation and oxidative stress to autism pathogenesis.
